Accro Bioscience to Present Phase Ib Data of AC-101, an Oral Selective RIPK2 Inhibitor, for Moderate-to-Severe UC at UEG Week 2026 in Barcelona

Summary

Accro Bioscience announced it will present Phase 1b efficacy and safety data for AC-101, an oral selective RIPK2 inhibitor, for moderate-to-severe ulcerative colitis at UEG Week 2026 in Barcelona. The presentation represents early-stage clinical progress for this immune-mediated disease therapeutic.